Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Boehringer Ingelheim
Colorcon
Mallinckrodt
Dow

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

Claims for Patent: 9,029,510

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,029,510
Title:Fully human antibodies that bind to VEGFR2 and methods of use thereof
Abstract: There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers.
Inventor(s): Gastwirt; Randy (San Diego, CA), Zhou; Heyue (San Diego, CA), Gray; John Dixon (San Diego, CA), Lu; Guodi (San Diego, CA)
Assignee: Sorrento Therapeutics, Inc. (San Diego, CA)
Application Number:13/854,071
Patent Claims:1. A fully human antibody of an IgG class that binds to a VEGFR2 [-] epitope, wherein the fully human antibody has a heavy chain variable domain sequence that is at least 95% identical to the amino acid sequences selected from the group consisting of SEQ ID NO. 9, SEQ ID NO. 23, SEQ ID NO. 51, SEQ ID NO. 63, SEQ ID NO. 73, and SEQ ID NO. 77, and that has a light chain variable domain sequence that is at least 95% identical to the amino acid sequences selected from the group consisting of SEQ ID NO. 10, SEQ ID NO. 24, SEQ ID NO. 52, SEQ ID NO. 64, SEQ ID NO. 74, SEQ ID NO. 78, and SEQ ID NO. 81.

2. The fully human antibody of claim 1, wherein the antibody has a heavy chain/light chain variable domain sequence selected from the group consisting of SEQ ID NO. 9/SEQ ID NO. 10, SEQ ID NO. 23/SEQ ID NO. 24, SEQ ID NO. 51/SEQ ID NO. 52, SEQ ID NO. 63/SEQ ID NO. 64, SEQ ID NO. 73/SEQ ID NO. 74, SEQ ID NO. 77/SEQ ID NO. 78, and SEQ ID NO. 77/SEQ ID NO. 81.

3. A fully human antibody Fab fragment, having a variable domain region from a heavy chain and a variable domain region from a light chain, wherein the heavy chain variable domain sequence that is at least 95% identical to the amino acid sequences selected from the group consisting of SEQ ID NO. 9, SEQ ID NO. 23, SEQ ID NO. 51, SEQ ID NO. 63, SEQ ID NO. 73, and SEQ ID NO. 77, and that has a light chain variable domain sequence that is at least 95% identical to the amino acid sequences selected from the group consisting of SEQ ID NO. 10, SEQ ID NO. 24, SEQ ID NO. 52, SEQ ID NO. 64, SEQ ID NO. 74, SEQ ID NO. 78, and SEQ ID NO. 81.

4. The fully human antibody Fab fragment of claim 3, wherein the antibody has a heavy chain/light chain variable domain sequence selected from the group consisting of SEQ ID NO. 9/SEQ ID NO. 10, SEQ ID NO. 23/SEQ ID NO. 24, SEQ ID NO. 51/SEQ ID NO. 52, SEQ ID NO. 63/SEQ ID NO. 64, SEQ ID NO. 73/SEQ ID NO. 74, SEQ ID NO. 77/SEQ ID NO. 78, and SEQ ID NO. 77/SEQ ID NO. 81.

5. A single chain human antibody, having a variable domain region from a heavy chain and a variable domain region from a light chain and a peptide linker connecting the heavy chain and light chain variable domain regions, wherein the heavy chain variable domain sequence that is at least 95% identical to the amino acid sequences selected from the group consisting of SEQ ID NO. 9, SEQ ID NO. 23, SEQ ID NO. 51, SEQ ID NO. 63, SEQ ID NO. 73, and SEQ ID NO. 77, and that has a light chain variable domain sequence that is at least 95% identical to the amino acid sequences selected from the group consisting of SEQ ID NO. 10, SEQ ID NO. 24, SEQ ID NO. 52, SEQ ID NO. 64, SEQ ID NO. 74, SEQ ID NO. 78, and SEQ ID NO. 81.

6. The fully human single chain antibody of claim 5, wherein the single chain fully human antibody has a heavy chain/light chain variable domain sequence selected from the group consisting of SEQ ID NO. 9/SEQ ID NO. 10, SEQ ID NO. 23/SEQ ID NO. 24, SEQ ID NO. 51/SEQ ID NO. 52, SEQ ID NO. 63/SEQ ID NO. 64, SEQ ID NO. 73/SEQ ID NO. 74, SEQ ID NO. 77/SEQ ID NO. 78, and SEQ ID NO. 77/SEQ ID NO. 81.

7. A method for treating a broad spectrum of mammalian cancers, comprising administering an effective amount of an anti-VEGFR2 polypeptide, wherein the anti-VEGFR2 polypeptide is selected from the group consisting of a fully human antibody of an IgG class that binds to a VEGFR2 epitope, a fully human antibody Fab fragment having a variable domain region from a heavy chain and a variable domain region from a light chain, a single chain human antibody having a variable domain region from a heavy chain and a variable domain region from a light chain and a peptide linker connecting the heavy chain and light chain variable domain regions; wherein the fully human antibody has a heavy chain variable domain sequence that is at least 95% identical to the amino acid sequences selected from the group consisting of SEQ ID NO. 9, SEQ ID NO. 23, SEQ ID NO. 51, SEQ ID NO. 63, SEQ ID NO. 73, and SEQ ID NO. 77, and that has a light chain variable domain sequence that is at least 95% identical to the amino acid sequences selected from the group consisting of SEQ ID NO. 10, SEQ ID NO. 24, SEQ ID NO. 52, SEQ ID NO. 64, SEQ ID NO. 74, SEQ ID NO. 78, and SEQ ID NO. 81; wherein the Fab fully human antibody fragment has the heavy chain variable domain sequence that is at least 95% identical to the amino acid sequences selected from the group consisting of SEQ ID NO. 9, SEQ ID NO. 23, SEQ ID NO. 51, SEQ ID NO. 63, SEQ ID NO. 73, and SEQ ID NO. 77, and that has a light chain variable domain sequence that is at least 95% identical to the amino acid sequences selected from the group consisting of SEQ ID NO. 10, SEQ ID NO. 24, SEQ ID NO. 52, SEQ ID NO. 64, SEQ ID NO. 74, SEQ ID NO. 78, and SEQ ID NO. 81; and wherein the single chain human antibody has the heavy chain variable domain sequence that is at least 95% identical to the amino acid sequences selected from the group consisting of SEQ ID NO. 9, SEQ ID NO. 23, SEQ ID NO. 51, SEQ ID NO. 63, SEQ ID NO. 73, and SEQ ID NO. 77, and that has a light chain variable domain sequence that is at least 95% identical to the amino acid sequences selected from the group consisting of SEQ ID NO. 10, SEQ ID NO. 24, SEQ ID NO. 52,SEQ ID NO. 64, SEQ ID NO. 74, SEQ ID NO. 78, and SEQ ID NO. 81.

8. The method for treating a broad spectrum of mammalian cancers of claim 7, wherein the fully human antibody has a heavy chain/light chain variable domain sequence selected from the group consisting of SEQ ID NO. 9/SEQ ID NO. 10, SEQ ID NO. 23/SEQ ID NO. 24, SEQ ID NO. 51/SEQ ID NO. 52, SEQ ID NO. 63/SEQ ID NO. 64, SEQ ID NO. 73/SEQ ID NO. 74, SEQ ID NO. 77/SEQ ID NO. 78, and SEQ ID NO. 77/SEQ ID NO. 81.

9. The method for treating a broad spectrum of mammalian cancers of claim 7, wherein the fully human antibody Fab fragment has both a heavy chain variable domain region and a light chain variable domain region wherein the antibody has a heavy chain/light chain variable domain sequence selected from the group consisting of SEQ ID NO. 9/SEQ ID NO. 10, SEQ ID NO. 23/SEQ ID NO. 24, SEQ ID NO. 51/SEQ ID NO. 52, SEQ ID NO. 63/SEQ ID NO. 64, SEQ ID NO. 73/SEQ ID NO. 74, SEQ ID NO. 77/SEQ ID NO. 78, and SEQ ID NO. 77/SEQ ID NO. 81.

10. The method for treating a broad spectrum of mammalian cancers of claim 7, wherein the fully human single chain antibody has both a heavy chain variable domain region and a light chain variable domain region, wherein the single chain fully human antibody has a heavy chain/light chain variable domain sequence selected from the group consisting of SEQ ID NO. 9/SEQ ID NO. 10, SEQ ID NO. 23/SEQ ID NO. 24, SEQ ID NO. 51/SEQ ID NO. 52, SEQ ID NO. 63/SEQ ID NO. 64, SEQ ID NO. 73/SEQ ID NO. 74, SEQ ID NO. 77/SEQ ID NO. 78, and SEQ ID NO. 77/SEQ ID NO. 81.

11. The method for treating a broad spectrum of mammalian cancers of claim 7, wherein the mammalian cancer to be treated is selected from the group consisting of solid tumors, blood borne tumors, leukemias, hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granuloumas.

12. A method for treating a broad spectrum of mammalian cancers, comprising administering an effective amount of an anti-VEGFR2 polypeptide and an antineoplastic agent: wherein the anti-VEGFR2 polypeptide is selected from the group consisting of a fully human antibody of an IgG class that binds to a VEGFR2 epitope, a fully human antibody Fab fragment having a variable domain region from a heavy chain and a variable domain region from a light chain, a single chain human antibody having a variable domain region from a heavy chain and a variable domain region from a light chain and a peptide linker connecting the heavy chain and light chain variable domain regions; wherein the fully human antibody has a heavy chain variable domain sequence that is at least 95% identical to the amino acid sequences selected from the group consisting of SEQ ID NO. 9, SEQ ID NO. 23, SEQ ID NO. 51, SEQ ID NO. 63, SEQ ID NO. 73, and SEQ ID NO. 77, and that has a light chain variable domain sequence that is at least 95% identical to the amino acid sequences selected from the group consisting of SEQ ID NO. 10, SEQ ID NO. 24, SEQ ID NO. 52, SEQ ID NO. 64, SEQ ID NO. 74, SEQ ID NO. 78, and SEQ ID NO. 81; wherein the antineoplastic agent is selected from the group consisting of anti-metabolites/anti-cancer agents, pyrimidine analogs, purine analogs, folate antagonists antiproliferative/antimitotic agents, vinca alkaloids, microtubule disruptors, taxane, vincristin, vinblastin, nocodazole, epothilones and navelbine, epidipodophyllotoxins actinomycin, amsacrine, anthracyclines, bleomycin, busulfan, camptothecin, carboplatin, chlorambucil, cisplatin, cyclophosphamide, cytoxan, dactinomycin, daunorubicin, doxorubicin, epirubicin, hexamethylmelamineoxaliplatin, iphosphamide, melphalan, merchlorehtamine, mitomycin, mitoxantrone, nitrosourea, plicamycin, procarbazine, taxol, taxotere, teniposide, triethylenethiophosphoramide, etoposide; antibiotics, dactinomycin (actinomycin D), daunorubicin, doxorubicin, idarubicin, anthracyclines, mitoxantrone, bleomycins, plicamycin, mitomycin; L-asparaginase; antiplatelet agents; antiproliferative/antimitotic alkylating agents, mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ethylenimines, methylmelamines, alkyl sulfonates-busulfan, nitrosoureas, trazenes--dacarbazinine (DTIC); antiproliferative/antimitotic antimetabolites; platinum coordination complexes, procarbazine, hydroxyurea, mitotane, aminoglutethimide; hormones, hormone analogs, aromatase inhibitors; anticoagulants; fibrinolytic agents, aspirin, dipyridamole, ticlopidine, clopidogrel, abciximab; antimigratory agents; antisecretory agents; immunosuppressives anti-angiogenic compounds; angiotensin receptor blocker; nitric oxide donors; anti-sense oligonucleotides; antibodies; cell cycle inhibitors, differentiation inducers; mTOR inhibitors, topoisomerase inhibitors, corticosteroids; growth factor signal transduction kinase inhibitors; mitochondrial dysfunction inducers, caspase activators; and chromatin disruptors.F

Details for Patent 9,029,510

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 1978-01-10 ⤷  Free Forever Trial 2039-02-26
Janssen Biotech, Inc. REOPRO abciximab Injection 103575 1994-12-22 ⤷  Free Forever Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Dow
Boehringer Ingelheim
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.